These results suggest that the inhibition of expression of survivin and Bcl-XL contributes to the TG101348-induced decrease in erlotinib-resistance in EGFR-mutant NSCLC cells. The gene discussed is BCL2L1; the disease is non-small cell lung carcinoma.